FibroBiologics, Inc. Common Stock
FBLGFibroBiologics, Inc. (FBLG) is a biotechnology company focused on the development and commercialization of regenerative medicine products derived from human fibroblast cells. The company primarily aims to create innovative therapies for wound healing, tissue repair, and other medical applications by leveraging its proprietary cell-based technology platforms.
Company News
FibroBiologics, a clinical-stage biotechnology company, closed a $4 million registered direct offering by issuing common stock and pre-funded warrants to an existing shareholder, with proceeds intended for general corporate purposes and debt satisfaction.
FibroBiologics completed a $4 million registered direct offering by selling common stock and pre-funded warrants to an existing shareholder, with the purchase price paid in gold coins. The company intends to use proceeds for general corporate purposes and debt satisfaction.
FibroBiologics, a clinical-stage biotechnology company, has demonstrated that fibroblasts administered intravenously can facilitate remyelination in an animal model of Cuprizone-induced demyelination. This finding builds on the company's previous report on remyelination in an experimental autoimmune encephalomyelitis (EAE) animal model, providing...
FibroBiologics, a clinical-stage biotech company, has demonstrated that intravenous fibroblasts can promote remyelination in a preclinical model of multiple sclerosis. This finding suggests the potential of fibroblast-based therapies for treating demyelinating diseases.
FibroBiologics, a clinical-stage biotechnology company, has filed a patent application for a new method to improve mitochondrial function using fibroblast-based therapies. This approach could lead to new treatment options for chronic diseases caused by mitochondrial dysfunction.
